Buscar

Estamos realizando la búsqueda. Por favor, espere...

 Detalle_Publicacion

Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain

Abstract: Introduction. Carbapenem-resistant Gram-negative (CRGN) infections are a major public health problem in Spain, often implicated in complicated, healthcare-associated infections that require the use of potentially toxic antibacterial agents of last resort. The objective of this study was to assess the clinical management of complicated infections caused by CRGN bacteria in Spanish hospitals. Methods. The study included: 1) a survey assessing the GN infection and antibacterial susceptibility profile in five participating Spanish hospitals and 2) a non-interventional, retrospective single cohort chart review of 100 patients with complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI), or hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/ VABP) attributable to CRGN pathogens. Results. In the participating hospitals CRGN prevalence was 9.3% amongst complicated infections. In the retrospective cohort, 92% of infections were healthcare-associated, and Klebsiella pneumoniae and Pseudomonas aeruginosa were the most common pathogens. OXA was the most frequently detected carbapenemase type (71.4%). We found that carbap enems were frequently used to treat cUTI, cIAI, HABP/VABP caused by CRGN pathogens. Carbapenem use, particularly in combination with other agents, persisted after confirmation of carbapenem resistance. Clinical cure was 66.0%, mortality during hospitalization 35.0%, mortality at the time of chart review 62.0%, and 6-months-post-discharge readmission 47.7%. Conclusion. Our results reflect the high burden and un met needs associated with the management of complicated infections attributable to CRGN pathogens in Spain and highlight the urgent need for enhanced clinical management of these difficult-to-treat infections.

 Fuente: Revista Española de Quimioterapia 2021;34(6): 639-650

Editorial: Sociedad española de quimioterapia

 Fecha de publicación: 22/11/2021

Nº de páginas: 12

Tipo de publicación: Artículo de Revista

 DOI: 10.37201/req/096.2021

ISSN: 0214-3429,1988-9518

Url de la publicación: http://www.doi.org/10.37201/req/096.2021

Autores/as

MASEDA, EMILIO

SALAVERT, MIGUEL

BOU, GERMAN

DÍAZ REGAÑÓN, JAZMÍN

LÓPEZ, DIEGO

LOZANO, VIRGINIA

GÓMEZ ULLOA, DAVID

FENOLL, RAQUEL

LARA, NURIA

MCCANN, EILISH